Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Fulvestrant/Palbociclib Doubles PFS in ESR1+ Advanced Breast Cancer

November 7th 2022

Fulvestrant plus palbociclib improved outcomes following an aromatase inhibitor plus palbociclib for patients with estrogen receptor–positive, HER2-negative advanced breast cancer with rising ESR1 mutation, according to updated findings from the phase 3 PADA-1 trial.

Investigators Highlight Top Advances at ESMO 2022

November 7th 2022

Data presented at the ESMO Congress 2022 highlighted advances across treatment modalities, including landmark data for trials in melanoma, breast cancer, and lung cancer, as well as early data that made headlines in a subgroup of patients with colon cancer.

Trilaciclib Reduces Sacituzumab Govitecan–Related AEs in Locally Advanced or Metastatic TNBC

November 2nd 2022

The administration of trilaciclib prior to treatment with sacituzumab govitecan meaningfully reduced adverse effects related to the antibody-drug conjugate in patients with unresectable locally advanced or metastatic triple-negative breast cancer, according to initial data from a phase 2 trial.

Trastuzumab Deruxtecan Produces Activity in Metastatic Breast Cancer With Brain Mets, Irrespective of HER2 Status

November 1st 2022

Fam-trastuzumab deruxtecan-nxki induced meaningful antitumor activity in patients with HER2-positive, HER2-low, or HER2-negative metastatic breast cancer who presented with brain metastases at baseline.

Ongoing Clinical Trials With ADC Therapy in HR+ Metastatic Breast Cancer

November 1st 2022

Breast medical oncologists close out the program on HR+ metastatic breast cancer by highlighting ongoing clinical trials with antibody-drug conjugate therapy.

Dr. Kang on Key Results From the PALOMA-2 and PALOMA-3 Trials in Advanced Breast Cancer

October 31st 2022

Irene Morae Kang, MD, discusses key overall survival data from the phase 3 PALOMA-2 and PALOMA-3 trials, which evaluated the addition of palbociclib to standard endocrine therapy for patients with advanced breast cancer.

Neoadjuvant Systemic Therapy Followed by Image-Guided Biopsy Lessens Surgical Need in Early-Stage Breast Cancer

October 27th 2022

Carefully selected patients with triple-negative or HER2-positive breast cancer who demonstrated pathologic complete responses to neoadjuvant systemic therapy as predicted by image-guided vacuum-assisted core biopsy avoided breast surgery and went on to standard radiotherapy.

Trastuzumab Deruxtecan Could Challenge Frontline Trastuzumab/Pertuzumab Combo in HER2+ Breast Cancer

October 27th 2022

Sara A. Hurvitz, MD, discusses the evolving treatment paradigm in HER2-positive breast cancer, ongoing research in the space, and developments in the treatment of triple-negative breast cancer.

OS Advances Gather Steam in Breast Cancer

October 27th 2022

The treatment of patients with breast cancer is making noteworthy strides in several clinical settings, with recent trial results showing overall survival improvements for advanced and metastatic disease.

Capivasertib Plus Fulvestrant Yields PFS Improvement in HR+ Locally Advanced or Metastatic Breast Cancer

October 26th 2022

Capivasertib plus fulvestrant generated a statistically and clinically significant improvement in progression-free survival in select patients with hormone receptor–positive, HER2-low or -negative, locally advanced or metastatic breast cancer.

Camizestrant Improves PFS Vs Fulvestrant in Advanced ER+ Breast Cancer

October 26th 2022

Camizestrant led to a statistically significant improvement in progression-free survival compared with fulvestrant in postmenopausal patients with estrogen receptor–positive, locally advanced, or metastatic breast cancer who were previously treated with endocrine therapy for advanced disease.

Dr. Ueno on Patient-Reported Outcomes With Trastuzumab Deruxtecan in HR+/HER2-Low Breast Cancer

October 26th 2022

Naoto T. Ueno, MD, PhD, FACP, discusses patient-reported outcomes with fam-trastuzumab deruxtecan-nxki (Enhertu) in hormone receptor (HR)–positive/HER2-low metastatic breast cancer.

Neoadjuvant Therapy and Surgical Advances Continue to Shift Treatment Options for Breast Cancer

October 25th 2022

Jeannie Shen, MD, discussed the shifts in surgical practice for patients with breast cancer, the need for a multidisciplinary approach to optimize treatment for individual patients, and ongoing efforts at Huntington Hospital and Cedars-Sinai to increase awareness and improve care for these patients.

HR+ Metastatic Breast Cancer: What is the Role of Antibody-Drug Conjugates?

October 25th 2022

Centering discussion on antibody-drug conjugates in HR+ metastatic breast cancer, panelists consider the selection and use of these agents in practice.

HER2-Low Metastatic Breast Cancer and Use of Trastuzumab Deruxtecan

October 25th 2022

Centering their discussion on the HER2 low setting of HR+ metastatic breast cancer, medical oncologists review data behind trastuzumab deruxtecan therapy.

Immunotherapy-Based Endeavors Could Alter Treatment Landscape in Metastatic TNBC

October 24th 2022

Yuan Yuan, MD, PhD, discusses the role immune checkpoint inhibitors have played in the treatment of triple-negative breast cancer, ongoing efforts to investigate the role of immunotherapy in breast cancer, and the work Cedars-Sinai is conducting to promote breast cancer awareness.

Real-World Data Could Help Inform Treatment Sequencing Decisions in HR+/HER2- Breast Cancer

October 24th 2022

Megan Kruse, MD, discusses the evolving treatment landscape in HR-positive, HER2-negative breast cancer, how the approval of fam-trastuzumab deruxtecan-nxki has affected sequencing choices in HER2-positive disease, and the importance of addressing racial disparities in breast cancer care.

Stark Differences in Mortality Rates Emphasize Ongoing Racial Disparities in Breast Cancer

October 24th 2022

Bridget A. Oppong, MD, discussed the importance of recognizing and addressing gaps in outcomes between patients with breast cancer in different racial groups. She also addressed the need for better advocacy for Black patients and advocated for improved screening guidelines to close the gap in racial disparities in breast cancer care.

Adjuvant Palbociclib Plus ET Does Not Prolong IDFS Over ET Alone in Stage IIA ER+ Breast Cancer

October 19th 2022

The addition of palbociclib to adjuvant endocrine therapy (ET) failed to improve invasive disease-free survival over ET alone in patients with estrogen receptor–positive, HER2-negative early breast cancer.

Experts Navigate the New World of HER2-Positive Metastatic Breast Cancer

October 19th 2022

Treatment decisions in the second-line setting for patients with HER2-positive metastatic breast cancer are not as cut-and-dried as deciding between which data have the best outcomes.